ストックスクリーナーアプリを入手
8.57
1.38%
-0.12
アフターアワーズ：
8.57
前日終値:
$8.69
開ける：
$8.66
24時間の取引高:
4.77M
Relative Volume:
1.11
時価総額：
$2.13B
収益：
$557.51M
当期純損益:
$-35.71M
株価収益率:
-47.61
EPS:
-0.18
ネットキャッシュフロー:
$15.50M
1週間 パフォーマンス:
+13.51%
1か月 パフォーマンス:
+33.49%
6か月 パフォーマンス:
+3.63%
1年 パフォーマンス:
+3.13%
1日の値動き範囲:
$8.385
$8.72
1週間の範囲:
$7.59
$8.86
52週間の値動き範囲:
$6.00
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
名前
Biocryst Pharmaceuticals Inc
セクター
電話
919-859-1302
住所
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
8.57 | 2.16B | 557.51M | -35.71M | 15.50M | -0.18 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-18 | 再開されました | Evercore ISI | Outperform |
| 2025-10-15 | 再開されました | TD Cowen | Buy |
| 2025-10-01 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-02-25 | 開始されました | Wedbush | Outperform |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-09-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-13 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-02-22 | アップグレード | Needham | Hold → Buy |
| 2022-11-02 | アップグレード | Evercore ISI | In-line → Outperform |
| 2022-08-05 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-08-05 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-04-18 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2022-04-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-12-10 | 開始されました | Oppenheimer | Outperform |
| 2021-08-06 | ダウングレード | Jefferies | Buy → Hold |
| 2021-08-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 開始されました | Cowen | Outperform |
| 2020-09-29 | 再開されました | JP Morgan | Overweight |
| 2020-06-17 | 開始されました | BTIG Research | Neutral |
| 2020-05-05 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-11-15 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 再開されました | Piper Jaffray | Overweight |
| 2018-08-08 | 再開されました | JP Morgan | Overweight |
| 2018-07-17 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 開始されました | Seaport Global Securities | Neutral |
| 2018-01-02 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 開始されました | Barclays | Equal Weight |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-09-06 | アップグレード | Jefferies | Hold → Buy |
| 2017-02-16 | 開始されました | Ladenburg Thalmann | Buy |
| 2016-08-12 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 繰り返されました | FBR Capital | Outperform |
| 2016-02-09 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2016-02-09 | ダウングレード | Needham | Buy → Hold |
すべてを表示
Biocryst Pharmaceuticals Inc (BCRX) 最新ニュース
BioCryst (BCRX) Grants Stock Units to New Employees - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Director Jill C. Milne receives 528 BCRX shares as board retainer grant - Stock Titan
Biocryst (NASDAQ: BCRX) director executes option exercise and share disposition - Stock Titan
Director Vincent Milano gets 848 BIOCRYST (BCRX) shares as equity retainer - Stock Titan
BIOCRYST (BCRX) director Steven Frank receives 1,285-share stock retainer grant - Stock Titan
Director Amy McKee receives stock retainer award at BioCryst (BCRX) - Stock Titan
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: Exploring a 146.81% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
BioCryst Pharmaceuticals (BCRX) Is Up 15.4% After First Profitable Year And HAE Portfolio ExpansionHas The Bull Case Changed? - Sahm
BioCryst at TD Cowen Conference: Strategic Growth and Future Prospects By Investing.com - Investing.com India
BCRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
[144] BIOCRYST PHARMACEUTICALS INC SEC Filing - Stock Titan
BioCryst (BCRX) stock price dips premarket as new navenibart HAE data lands; Cowen talk next - TechStock²
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Net Income Turns Positive And Astria Deal Expands HAE Portfolio - Yahoo Finance
BioCryst’s First Profitable Year Recasts Hereditary Angioedema Growth Story - Yahoo Finance
Price-Driven Insight from (BCRX) for Rule-Based Strategy - Stock Traders Daily
BioCryst (BCRX) Soars 10.8% on Swing to Profits - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and Fate Therapeutics (FATE) - The Globe and Mail
BioCryst Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BCRX SEC FilingsBiocryst Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 10.7% After Earnings Beat - MarketBeat
Wedbush Adjusts Price Target on BioCryst Pharmaceuticals to $22 From $21, Maintains Outperform Rating - marketscreener.com
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2025 Earnings Call Transcript - Insider Monkey
10 Stocks Ending February With a Bang - Insider Monkey
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
BioCryst Pharmaceuticals Inc (BCRX): A Strategic SWOT Insight - GuruFocus
Where is BioCryst Pharmaceuticals (BCRX) Headed According to the Street? - Yahoo Finance
BioCryst: Q4 Earnings Snapshot - theheraldreview.com
BioCryst Pharmaceuticals Inc (BCRX) Q4 2025 Earnings Call Highli - GuruFocus
BCRX: $400M Blackstone term loan funds Astria deal, secured by assets, matures 2031, SOFR+4.5% - TradingView
TD Cowen reiterates BioCryst Pharma stock Buy rating on Orladeyo growth By Investing.com - Investing.com South Africa
TD Cowen reiterates BioCryst Pharma stock Buy rating on Orladeyo growth - Investing.com
BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Quarterly Earnings Results, Beats Expectations By $1.05 EPS - MarketBeat
BioCryst Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:BCRX) 2026-02-26 - Seeking Alpha
BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
BioCryst Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Earnings call transcript: BioCryst Q4 2025 sees EPS and revenue beat - Investing.com
BioCryst Pharmaceuticals' Q4 Swings to Earnings; Revenue Rises - marketscreener.com
BIOCRYST PHARMACEUTICALS ($BCRX) Releases Q4 2025 Earnings - Quiver Quantitative
Q4 2025 BioCryst Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q4 Total Revenue $406.6M - marketscreener.com
Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q4 EPS $1.12 - marketscreener.com
BioCryst Boosts HAE Franchise With Astria Acquisition, Guidance - TipRanks
BioCryst: Fourth Quarter Financial Highlights - Bitget
BioCryst (BCRX) Achieves Record Revenue and Profitability Milest - GuruFocus
BioCryst Pharmaceuticals (BCRX) Projects Orladeyo Revenue to Rea - GuruFocus
BioCryst Pharmaceuticals : BCRX Q4 2025 Earnings Presentation - marketscreener.com
Rare-disease drugmaker BioCryst turns first annual profit, wins FDA OK for kids - Stock Titan
BioCryst Pharmaceuticals Inc (BCRX) Q4 2025 Earnings Call Highlights: Record Profitability and ... By GuruFocus - Investing.com Canada
Are BioCryst Pharmaceuticals (BCRX) Shares Offering Value After Recent Price Rebound - Yahoo Finance
Biocryst Pharmaceuticals Inc (BCRX) 財務データ
収益
当期純利益
現金流量
EPS
0.18%
1.85%
大文字化:
|
ボリューム (24 時間):